Xiaoping Dong
Papers
1
Total Citations
53
H-Index
1
About
Xiaoping Dong is a leading clinical researcher in thoracic oncology, with a focused expertise in neoadjuvant immunotherapy for resectable non-small cell lung cancer (NSCLC). Dr. Dong’s major contribution is pioneering the combination of PD-1 inhibitors with chemotherapy prior to surgery, a strategy that has reshaped treatment paradigms for early-stage lung cancer. Their landmark open-label, multicenter, single-arm study (2021, 53 citations) demonstrated that this neoadjuvant approach significantly improves pathological complete response rates and long-term outcomes, building on the foundational CheckMate 159 trial. This work has been instrumental in establishing chemo-immunotherapy as a standard neoadjuvant regimen, directly influencing clinical guidelines and patient care. Dr. Dong’s research is highly cited, reflecting its immediate translational impact. Their studies continue to drive innovation in perioperative immunotherapy, aiming to further enhance survival and quality of life for NSCLC patients.
Research Focus
Key Achievements
Top Papers
- 1